The Present Situation of PGx/PGt Study in Japan - JHSF Questionnaire Survey - Daiichi Pharmaceutical Co., Ltd. Osamu Sato Ph.D. [email protected] Tackling of JHSF JHSF (Japan Health Sciences Foundation) was established by 128 companies in April, 1986, under the support of the MHLW (MHW at that time) The mission of JHSF is promoting of basic and advanced technologies related to medicine, drugs and of contributing to human health and welfare Since 1998, JHSF has continuously performed the investigation of the tendencies and future views of genome sciences and has offered reports every year In the report for 2002 JHSF performed a questionnaire survey in order to know the present situation of PGx/PGt in Japan JHSF Questionnaire Survey Purpose: Grasp of the PGx/PGt Present Situation in Japan Term: September 27 to November 1, 2002 Target: 91 JHSF Member Companies Method: Questionnaire Survey by Mail Recovery: 53 Companies(44 valid) Breakdown of the 44 companies: 37 Pharmaceuticals and 7 Others Questionnaire Items 1. 2. 3. 4. 5. 6. Study of a relationship between developing drugs and gene polymorphism Problems related to ethics in PGx/PGt studies Problems related to the method of PGx/PGt study Problems on application using the results of PGx/PGt studies Post-marketing PGx/PGt study Problems related to the marketing of PGx/PGt-related drugs etc. 1. Do you have any plans to conduct PGx/PGt study with developing drugs ? Replies 16 27 43 Yes No Total % 37.2 62.8 100.0 Yes 37% No 63% (n=43) Studies conducting or scheduled to be conducted in 2 or 3 years : conducting 0 : scheduled 5 Relating to drug metabolism 4 10 6 (n=10) Relating to drug reactivity (n=10) 3 7 2. Do you have any plans to conduct PGx/PGt study with post-marketing drugs ? Replies 5 34 39 Yes No Total Objectives % 12.8 87.2 100.0 No 87% (n=39) 1 特定の副作用発現との関連を明ら Adverse Reaction かにする 2 3 4 5 2 レスポンダー/ノンレスポンダー Respnder/Non-Responder を明らかにする 4 Exclusive Intention 競合品との差別化を図る 0 Others Yes 13% 0 その他 0 Reason of “No” (n=5) 0 10 Cost Effectiveness 2 Difficulty in Collaboration with Institution 1 Difficulty in getting IC 2 No Proper Drug Others 20 30 29 2 (n=33) 3. What do you think about the necessity of guidelines for conducting PGx/PGt studies ? Not familiar with this problem Necessary Replies 35 % Not necessary 10% 85.4 5% 4.9 Not necessary 2 Not familiar with this problem 4 9.8 41 100.0 Total Necessary 85% (n=41) 4. Are you concerned about decreases in the patients number by PGx/PGt study ? Replies A higher price, which compensate the decrease in the number of patients, may not be accepted. Not familiar with this problem 21% (8) No 13% (5) (n=39) Yes 66% (26) % 14 58.3 8 33.3 Objection from the sales division. 14 58.3 Patients may not accept gene testing. 20 83.3 2 8.3 Patients may prefer less effective drugs prescribed without gene testing. Other Replies from 24 companies 5. What do you expect for MHLW if you will develop drugs for the non-responders ? Orphan-development 24 Financial support 10 Registration without Phase III 6 Premium NHI price 14 No idea 4 Others 1 0 (n=38) 5 10 15 20 25 Summary of the Survey Difficulties in finding appropriate methodologies Not clear relationship between GCP and “Common Ethical Guideline” Decreased number of patients Preparation of new ethical guideline for PGx/PGt Establishment of system to conduct retrospective PGx/PGt study Premium addition on regular NHI price
© Copyright 2024 ExpyDoc